TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in the general wellbeing of the subject
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Analysis of gastrointestinal, oropharyngeal, lung and/or blood specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Analysis of gastrointestinal, oropharyngeal, lung and/or blood specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Analysis of gastrointestinal, oropharyngeal, lung and/or blood specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rate of acute rejection reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline for Serum Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline for Serum Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline for Serum Intact Parathyroid Hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Histologic regression of Barrett esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for sudden-death event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to correct diagnosis by head to pelvis CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost analysis of head to pelvis CT scan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Sexually Transmitted Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-reported Numbers of Unintended Pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Skin prick test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Freedom from major VARC-2 events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in therapeutic regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Continuous Performance Task (CPT) Response Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Continuous Performance Task (CPT) Response Time Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported ADHD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serum concentration of fenofibric acid AUC (0-24hrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: level of metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin, and syndecan -1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF outflow resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Severe Impairment Battery (SIB) Score at Week 26
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (Severe) (ADCS-ADLsev) Score at Week 26
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinician Administered Assessment of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of extension of uterine incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Injury of the vagina
Endpoint domain: Adverse events/effects
Primary endpoint: Injury of the bladder
Endpoint domain: Adverse events/effects
Primary endpoint: Injury of the ureter
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Completed the Study
Endpoint domain: Mortality/survival
Primary endpoint: Seven-days Average Sedentary Time (Minutes/Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gambling severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with each COMT genotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veno-occlusive disease incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic effects of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic evaluation of belinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of Cutting Guide Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cardiorespiratory evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: autonomic nervous system evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sleep evaluation
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Ovarian reserve markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Trough Forced Expiratory Volume in One Second Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percentage of allele B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Glutathione
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of overall response (DoR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Children Depression Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants reporting having an HIV test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With New or Recurrent AIDS Event, or Death
Endpoint domain: Mortality/survival
Primary endpoint: Radiologic slippage of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children experiencing a treatment failure
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability and safety
Endpoint domain: Adverse events/effects
Primary endpoint: analyte concentrations from blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of Major Adverse Cardiac Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body Dissatisfaction Subscale of the Eating Disorder Symptom Inventory (EPSI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in QTc measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Molecular Response Rate (MMR) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations of Antibodies Against Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hand eczema severity index (HECSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants completing the treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average number of sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and types of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in clinical lab assessments and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until Cessation of Oral Shedding of SARS-CoV-2 Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction of S. Aureus Transmission
Endpoint domain: Adverse events/effects
Primary endpoint: Six-months progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Negative Predictive Value of histology prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change Sperm Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change Sperm Vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Sperm DNA Fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change Sperm APOPTOSIS (Annexin V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: JEBSEN Hand Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of specific inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ionized Calcium in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progressive disease (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response based on MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent signal change in BOLD response to a working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N-acetyl aspartate (NAA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of cetuximab administration
Endpoint domain: Adverse events/effects
Primary endpoint: Self-Report Receipt of HIV Test Results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Risky Sexual Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Micafungin plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Consonants Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) on Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants Receiving MK-8266 or Placebo Who Experienced At Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in psychological pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healing of Groin Wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Circadian phase timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (area-under-the-serum-insulin concentration time curve) 0 - 240 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cmax (maximum serum insulin concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Asthma related maternal/fetal morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Endoscopic Interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful vaginal delivery
Endpoint domain: Mortality/survival
Primary endpoint: Active Knee Extension Test (AKE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Correct Identification of Pre-treatment Photographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of BRL 49653C compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in biologically confirmed sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in proportion of unprotected sexual acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of patients with Steroid-Free Colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of cells with reduced viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of cells in G2/M arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in immune tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Days Needed to Recover From Delayed Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Classified as a Responder
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in Bi-dimensional Tumor Area or Appearance of New Brain Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: site of mucosa affected by oral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment emergent adverse and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time of occurrence of Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in VAS (visual analog scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in ODI (Oswestry Disability Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in SF-36 (Short Form (36) Health Survey)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relief of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of indomethacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA-PFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity-related discontinuation of radionuclide treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Berg balance scale at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Trunk impairment scale at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial late enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neck volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jowls at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular definition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients developing Chronic Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of participants screened as eligible who enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who enrolled who completed the 8 week-trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tolerability of Meditation Intervention on a 10-point Likert scale
Endpoint domain: Adverse events/effects
Primary endpoint: Inter-jugale width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal maxillary width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density of the mid-palatal suture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post installation pain/stinging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants retained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of intervention arm participants who complete study visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Reaction Time for Computerized Color Naming Stroop Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Accuracy Rates Using Computerized Color Naming Stroop Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With no Fluid on OCT at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Visual Acuity From Baseline to Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) Following IV Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nasal endoscopy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow-mediated Arterial Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Levels of High Sensitivity C-reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PANSS negative symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: albumin-to-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of participants with clinical relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalisation of muscle sympathetic nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vital signs (blood pressure, pulse rate, body temperature)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory variables (high sensitivity C-reactive protein, circulating neutrophils)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-tlast]) of Loratadine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Loratadine in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1C at Week 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in light touch sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of combined CG1940 & CG8711
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of antibiotic-associated diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of subjects experiencing AEs and/or SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and rate of Acute Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expression level of MXRA5 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of meals/beverages suspected to contain the studied food additives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection (blood stream or local wound)
Endpoint domain: Adverse events/effects
Primary endpoint: asymptomatic venous thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: symptomatic venous thrombosis with positive confirmatory image tests
Endpoint domain: Adverse events/effects
Primary endpoint: TIVAD catheter occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: major mechanical failure, dislocation of TIVAD
Endpoint domain: Adverse events/effects
Primary endpoint: Level greater than 25ng
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Stable BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neurotransmitter concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes